Methods for treatment of mental and/or mood disorders in a subject are disclosed. The methods comprise administration to a subject in need thereof an effective amount of 2-bromo-LSD and/or a mTOR inhibitor. Also disclosed are pharmaceutical compositions that comprise 2-bromo-LSD and/or a mTOR inhibitor as well as dosage formulations and dosage regimes thereof.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
2.
METHODS OF TREATING MENTAL OR MOOD DISORDERS USING 2-BROMO-LSD
Methods using 2-Bromo-LSD or a derivative or salt thereof to treat subjects suffering from mental and/or mood disorders. The 2-Bromo-LSD is provided as a pharmaceutical composition formulated in a variety of manners for resolving symptoms even in subjects who have failed prior therapy. Methods comprise or consist of administering 2-bromolysergic acid diethylamide or a derivative or salt thereof to a subject in need of.
LSD derivative compounds and polymorphs thereof, methods for their synthesis, compositions and treatment of diseases and disorders are described herein, the compounds having the structure of Formula (I):, including pharmaceutically acceptable salts, hydrates, solvates, tautomers, enantiomers, diastereomers, racemates, polymorphs or combinations thereof; wherein: R1 to R14 are each independently selected from H, or a substituted or unsubstituted hydrocarbon group and X is selected from a halo group.
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07D 307/62 - Three oxygen atoms, e.g. ascorbic acid
Implantable product(s) and methods for predetermined release of one or more active pharmaceutical ingredients (APIs). More specifically, implantable, subcutaneous product(s) and methods for treating depression and other mental and/or mood disorders and/or for prevention and/or mitigation of abuse of the one or more APIs, which may lead to addiction, intoxication, overdose, and/or death.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
C07C 215/30 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
C07C 225/16 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
Methods for treatment of mental and/or mood disorders in a subject are disclosed. The methods comprise administration to a subject in need thereof an effective amount of 2-bromo-LSD and/or a mTOR inhibitor. Also disclosed are pharmaceutical compositions that comprise 2-bromo-LSD and/or a mTOR inhibitor as well as dosage formulations and dosage regimes thereof.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 25/00 - Drugs for disorders of the nervous system
Disclosed herein are compositions, methods and uses for treating a sedative, hypnotic, or anxiolytic use disorder and related disorders. In some embodiments, the compositions comprise dihydrohonokiol-B ("DHH-B") and at least one pharmaceutically acceptable carrier, wherein the DHH-B is present in an amount ranging from between about 0.5% to about 25% by total weight of the composition. In other embodiments, the compositions comprise dihydrohonokiol-B ("DHH-B") and at least one pharmaceutically acceptable carrier, wherein the DHH-B is present in an amount ranging from between about 0.000001% to about 5% by total weight of the composition.
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
8.
METHODS OF TREATING MENTAL OR MOOD DISORDERS USING 2-BROMO-LSD
Methods using 2-Bromo-LSD or a derivative or salt thereof to treat subjects suffering from mental and/or mood disorders. The 2-Bromo-LSD is provided as a pharmaceutical composition formulated in a variety of manners for resolving symptoms even in subjects who have failed prior therapy. Methods comprise or consist of administering 2-bromolysergic acid diethylamide or a derivative or salt thereof to a subject in need of.
Transdermal cannabinoid formulations comprising a versatile cannabinoid stock provided as a variety of cosmetic delivery systems providing enhanced cannabinoid absorption, and more controlled release into vascular and/or lymphatic systems for greater efficacy and a desirable subject experience. The cannabinoid stock is a substantially homogeneous concentrated stable cannabinoid emulsion characterized as a cannabinoid load capacity carrier that comprises emulsified particles of stabilized cannabinoid/lipid.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
A process of synthesizing 2-bromo-LSD or a salt or hydrate thereof comprising the steps of reacting methylergometrine with a brominating agent to produce [(1S)-1-(Hydroxymethyl)propylamino][(6aR,9R)-5-bromo-7-methyl-4,7-diaza-4,6,6a,7,8,9-hexahydroacephenanthrylen-9-yl]formaldehyde as a first intermediate, and then hydrolyzing [(1S)-1-(Hydroxymethyl)propylamino][(6aR,9R)-5-bromo-7-methyl-4,7-diaza-4,6,6a,7,8,9-hexahydroacephenanthrylen-9-yl]formaldehyde to yield bromo-lysergic acid as a second intermediate, wherein bromo-lysergic acid is then amidated to yield 2-bromo-LSD or a salt or hydrate thereof.
A process of synthesizing 2-bromo-LSD or a salt or hydrate thereof comprising the steps of reacting methylergometrine with a brominating agent to produce [(1S)-1-(Hydroxymethyl)propylamino][(6aR,9R)-5-bromo-7-methyl-4,7-diaza-4,6,6a,7,8,9-hexahydroacephenanthrylen-9-yl]formaldehyde as a first intermediate, and then hydrolyzing [(1S)-1-(Hydroxymethyl)propylamino][(6aR,9R)-5-bromo-7-methyl-4,7-diaza-4,6,6a,7,8,9-hexahydroacephenanthrylen-9-yl]formaldehyde to yield bromo-lysergic acid as a second intermediate, wherein bromo-lysergic acid is then amidated to yield 2-bromo-LSD or a salt or hydrate thereof.
C07D 457/00 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid
patents
